Share Price | Kiniksa Pharmaceuticals International Plc Stock Analysis & Recommendation

Q: Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?

As of 11 August 2025, the valuation grade for Kiniksa Pharmaceuticals International Plc moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its P/E ratio of 565.79, which is significantly higher than the industry average, and an EV to EBITDA ratio of 402.35. Additionally, the absence of a PEG ratio suggests that traditional growth metrics may not apply, further complicating the valuation landscape.In comparison to its peers, Kiniksa's high P/E ratio stands out, with no direct peer provided for a more comprehensive analysis. The recent stock performance shows that Kiniksa has outperformed the S&P 500 year-to-date with a return of 81.60% compared to the index's 12.22%, reinforcing the notion that the stock is gaining traction in the market despite its high valuation ratios.

Q: Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?

As of 1 October 2023, Kiniksa Pharmaceuticals International Plc is currently in a bullish technical stance, supported by multiple indicators. The MACD is bullish on both the weekly and monthly time frames, and the moving averages are bullish on the daily chart. Additionally, the KST and Dow Theory both indicate a bullish trend on weekly and monthly bases. The Bollinger Bands show a mildly bullish stance on the weekly and bullish on the monthly. The OBV is mildly bullish weekly and bullish monthly.In terms of performance, Kiniksa has outperformed the S&P 500 significantly year-to-date with a return of 81.60% compared to the S&P 500's 12.22%, and it also shows strong returns over the 1-year and 3-year periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

248.47 k

Shareholding (Mar 2026)

FII

17.09%

Held by 111 FIIs

DII

82.49%

Held by 38 DIIs

Promoter

0.41%

Is Kiniksa Pharmaceuticals International Plc overvalued or undervalued?

20-Sep-2025

As of August 11, 2025, Kiniksa Pharmaceuticals International Plc's valuation has shifted from fair to attractive, indicating it may be undervalued despite a high P/E ratio of 565.79 and an EV to EBITDA ratio of 402.35, while outperforming the S&P 500 with an 81.60% year-to-date return.

View full answer

Is Kiniksa Pharmaceuticals International Plc technically bullish or bearish?

20-Sep-2025

As of October 1, 2023, Kiniksa Pharmaceuticals is in a bullish technical position, with positive indicators across multiple time frames, and has significantly outperformed the S&P 500 year-to-date with an 81.60% return compared to 12.22%.

View full answer

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Profit of 59.11%, the company declared Outstanding results in Mar 26

The company has declared positive results for the last 5 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 165.86 MM
ROCE(HY) Highest at 13.74%
DEBT-EQUITY RATIO (HY) Lowest at -75.79 %

With ROE of 10.40%, it has a very attractive valuation with a 6.17 Price to Book Value

High Institutional Holdings at 100%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3,501 Million (Small Cap)

P/E

59.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.72

Return on Equity

-999,999.00%

Price to Book

6.17

Revenue and Profits:

Net Sales:

214 Million

(Quarterly Results - Mar 2026)

Net Profit:

23 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

29.21%

6 Months

39.91%

1 Year

107.14%

2 Years

219.67%

3 Years

284.8%

4 Years

457.02%

5 Years

315.43%

Kiniksa Pharmaceuticals International Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

268.40%

EBIT Growth (5y)

20.02%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.17

EV to EBIT

40.02

EV to EBITDA

39.23

EV to Capital Employed

19.74

EV to Sales

4.56

PEG Ratio

Dividend Yield

ROCE (Latest)

49.34%

ROE (Latest)

10.40%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 65 Schemes (33.29%)

Foreign Institutions

Held by 111 Foreign Institutions (17.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6.04% vs 11.72% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 59.15% vs -22.83% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "214.30",
          "val2": "202.10",
          "chgp": "6.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "29.70",
          "val2": "20.20",
          "chgp": "47.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "22.60",
          "val2": "14.20",
          "chgp": "59.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "136.60%",
          "val2": "97.80%",
          "chgp": "3.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 60.11% vs 56.57% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 236.57% vs -406.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "677.60",
          "val2": "423.20",
          "chgp": "60.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "78.80",
          "val2": "-43.90",
          "chgp": "279.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "59.00",
          "val2": "-43.20",
          "chgp": "236.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "114.00%",
          "val2": "-107.80%",
          "chgp": "22.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]